COCHLEAR LIMITED (COH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

COH - COCHLEAR LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Cochlear is a medical device company that designs, manufactures and supplies hearing implants to the global market. Formed in 1981 with finance from the Australian government, it became a listed entity in 1995, and has grown to become the global leader in its field.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$216.95

18 May
2022

4.970

OPEN

$215.06

2.34%

HIGH

$217.42

87,554

LOW

$214.05

TARGET
$227.583 4.9% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . CGS . CU6 . TRJ . EBR . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
COH: 1
Title FY20
Actual
FY21
Actual
FY22
Forecast
FY23
Forecast
EPS (cps) xxx 496.7 427.7 xxx
DPS (cps) xxx 255.0 290.0 xxx
EPS Growth xxx N/A - 13.9% xxx
DPS Growth xxx 59.4% 13.7% xxx
PE Ratio xxx N/A 50.1 xxx
Dividend Yield xxx N/A 1.4% xxx
Div Pay Ratio(%) xxx 51.3% 67.8% xxx

Dividend yield today if purchased 3 years ago: 1.27%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

1.19

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 155c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
Title 201620172018201920202021
EPS Basic xxxxxxxxxxxxxxx496.7
DPS All xxxxxxxxxxxxxxx255.0
Sales/Revenue xxxxxxxxxxxxxxx1,493.3 M
Book Value Per Share xxxxxxxxxxxxxxx2,588.4
Net Operating Cash Flow xxxxxxxxxxxxxxx271.3 M
Net Profit Margin xxxxxxxxxxxxxxx21.86 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201620172018201920202021
Return on Capital Employed xxxxxxxxxxxxxxx21.04 %
Return on Invested Capital xxxxxxxxxxxxxxx18.03 %
Return on Assets xxxxxxxxxxxxxxx13.00 %
Return on Equity xxxxxxxxxxxxxxx21.04 %
Return on Total Capital xxxxxxxxxxxxxxx16.30 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx154.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Credit Suisse

28/04/2022

1

Outperform

$240.00

10.62%

Cochlear will acquire Demant's implant division, Oticon Medical, for $170m, adding $75-80m in annual revenue, although Credit Suisse notes the division is currently loss-making. The company's aim is to make it profitable.

Demand had issued a recall of its non-implanted Oticon implants in October 2021, temporarily halting sales of new implants amid an issue with loss of the hermiticity in a small number of these.

Cochlear will not be assuming any liability for issues that may arise from the recall.

Credit Suisse considers this a minor deal but a strategic move that removes the risk of another player entering the US market and competing more aggressively. Outperform rating and $240 target maintained.

FORECAST
Credit Suisse forecasts a full year FY22 dividend of 300.00 cents and EPS of 428.00 cents.
Credit Suisse forecasts a full year FY23 dividend of 341.00 cents and EPS of 488.00 cents.

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

COH STOCK CHART